siRNA with Modified Nucleotides for GST-pi Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current siRNA agents for modulating GST-π expression in cancer tissues face challenges such as insufficient activity, off-target effects, and lack of serum stability, limiting their efficacy in treating malignant tumors.
Innovation Solution
Development of nucleic acid molecules, including siRNA with modified nucleotides and structures, specifically designed to inhibit GST-π expression, which are formulated with lipid molecules or liposomes for enhanced stability and reduced off-target activity, allowing for effective gene silencing and tumor inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional siRNA agents are used to modulate GST-π expression, then gene silencing activity is achieved, but serum stability is insufficient and off-target effects occur
Solution Approach 1:
The patent modifies the chemical structure of siRNA molecules by incorporating 2'-deoxy nucleotides, 2'-O-alkyl substituted nucleotides, and 2'-deoxy-2'-fluoro substituted nucleotides at specific positions. These chemical parameter changes enhance serum stability while maintaining gene silencing activity, directly resolving the contradiction between reliability and stability.
Solution Approach 2:
The patent creates composite siRNA structures by combining modified nucleotides (2'-deoxy, 2'-O-alkyl, 2'-deoxy-2'-fluoro) with standard nucleotides in specific patterns. This composite approach provides both the stability of modified nucleotides and the functional activity of the siRNA molecule, simultaneously achieving serum stability and gene silencing efficacy.
2Reliability
If conventional siRNA agents are used to modulate GST-π expression, then gene silencing activity is achieved, but off-target effects increase
Solution Approach 1:
The patent introduces specific parameter changes in the nucleotide structure (2'-deoxy-2'-fluoro substitutions) that enhance the precision of target recognition. These modifications reduce off-target effects by improving the discrimination between target and non-target sequences, while maintaining potent on-target gene silencing activity.
Solution Approach 2:
The patent applies modified nucleotides at specific local positions within the siRNA sequence (particularly in the seed region and at specific offsets from the 5' end). This localized modification strategy optimizes target specificity at critical positions while preserving overall gene silencing function, thereby reducing off-target effects.
3Stability of the object's composition
If siRNA molecules with modified nucleotides are designed to enhance stability, then serum stability and reduced off-target effects are achieved, but molecular structure complexity increases
Solution Approach 1:
The patent systematically varies nucleotide parameters (2'-deoxy, 2'-O-alkyl, 2'-deoxy-2'-fluoro) at defined positions to achieve stability enhancements. While this does increase molecular complexity, the structured approach using specific modification patterns provides a rational design framework that balances complexity with functional benefits.
Solution Approach 2:
The patent discards the problematic feature of using unmodified, unstable siRNA sequences and recovers functionality through strategically placed nucleotide modifications. By selectively modifying only critical positions rather than the entire molecule, the patent minimizes unnecessary complexity while achieving the desired stability and specificity improvements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The siRNA molecules demonstrate significant tumor inhibition, increased serum stability, and reduced off-target effects, achieving a potent and specific knockdown of GST-π mRNA levels, thereby effectively treating malignant tumors and cancer associated with mutated KRAS.
Implementation Method 1
This invention relates to compounds, compositions and methods for modulating the expression of human GST-π using RNA interference
Implementation Method 2
the nucleic acid molecules may contain one or more nucleotides that are modified or chemically-modified... 2'-deoxy nucleotides, 2'-O-alkyl substituted nucleotides, 2'-deoxy-2'-fluoro substituted nucleotides
Implementation Method 3
formulated with lipid molecules or liposomes for enhanced stability and reduced off-target activity
Data Source
AI summary
Compounds, compositions and methods for modulating the expression of human GST-π using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2′-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.